Use of drug eluting stents: Expert consensus of the French Society of Cardiology

Archives of Cardiovascular Diseases

Volumn 101, Issue 3, 2008, Pages 190-193

  Danchin, N ^a   Blanchard, D ^b   Chevalier, B ^b   Eltchaninoff, H ^b   Ferrieres J ^b   Steg, P G ^b   Machecourt, J ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ANGIOPLASTY; BLEEDING; BRACHYTHERAPY; CARDIOVASCULAR DISEASE; CORONARY ARTERY BYPASS GRAFT; DEATH; DRUG ELUTING STENT; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; MORTALITY; RESTENOSIS; REVIEW; THROMBOSIS;

EID: 44449153770     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1875-2136(08)71802-3     Document Type: Article

References (37)

1. Moses JW, Leon MB, Popma JJ, C et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. SIRIUS Investigators. N Engl J Med 2003;349:1315-23.
2. Stone GW, Ellis SG, Cox DA, et al; TAXUS-IV Investigators. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004;109:1942-7.
3. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of Sirolimus and Paclitaxel-Eluting Stents. N Engl J Med 2007;356:998-08.
4. Guidance document of the National Institute of Clinical Excellence (NICE), 7 Aug 2007, www.nice.org.uk
5. Jiménez-Quevedo P, Sabaté M, Angiolillo DJ, et al. for the DIABETES Investigators. Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. Eur Heart J 2007;16:1946-52.
6. Grube E, Dawkins KD, Guagliumi G, et al. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. Eur Heart J 2007;28:2578-82.
7. Kastrati A, Mehili J, von Beckerath N, et al for the ISAR-DESIRE Study. Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis. A Randomized Controlled Trial. JAMA 2005;293:165-71.
8. Kastrati A, Mehili J, Pache J, et al. Analysis of 14 Trials Comparing Sirolimus-Eluting Stents with Bare-Metal Stents. N Engl J Med 2007;356:1030-9.
9. Stettler C, Wandel S, Alleman S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 2007;370:937-48.
10. Mauri L, Hsieh WH, Massaro JM, et al. Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents. N Engl J Med 2007;356:1020-9.
11. Machecourt J, Danchin N, Lablanche JM. Risk Factors for Stent Thrombosis After Implantation of Sirolimus-Eluting Stents in Diabetic and Nondiabetic Patients. The EVASTENT Matched-Cohort Registry J Am Coll Cardiol 2007;50:501.
12. Win HK for the EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007;297:2001.
13. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting : perspectives from multicenter clinical trials. J Am Coll Cardiol 2002;40:2082-90.
14. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30.
15. Valgimigli M, Dawkins K, Macaya C, et al. Impact of stable versus unstable coronary artery disease on 1-year outcome in elective patients undergoing multivessel revascularization with sirolimus-eluting stents: a subanalysis of the ARTS II trial. J Am Coll Cardiol. 2007;49:431-41.
16. Spertus JA, Dawson J, Masoudi FA, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-9.
17. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-02.
18. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007;116:e148-304.
19. Food and Drug Aadministration. http://www.fda.gov/cdrh/news/010407.html
20. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2007 2007;28:1598-660.
21. Bhatt DL, Topol EJ. Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance Executive Committee. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004;148:263-8.
22. Bhatt DL, Flather MD, Hacke W, et al. for the CHARISMA investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007;49:1982-8.
23. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-78.
24. Jeremias A, Sylvia B, Bridges J, et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004; 109: 1930-2
25. Spaulding C, Henry P, Teiger E, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med 2006; 355: 1093-104
26. Laarman GJ, Suttorp MJ, Dirksen MT, et al. Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. N Engl J Med 2006; 355: 1105-13
27. Daemen J, Tanimoto S, Garcia-Garcia HM, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from RESEARCH and T-SEARCH registries). Am J Cardiol 2007;99:1027-32.
28. Fox K, Alonso Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary. The Task Force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341-81.
29. Chieffo A, Stankovic, Bonizzoni E, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005;111:791-5.
30. Park SJ, Kim YH, Lee SW, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis. J Am Coll Cardiol 2005;45:351-6.
31. Cohen DJ, Murphy SA, Baim DS, et al. Cost-Effectiveness of Sirolimus-Eluting Stents for Treatment of Complex Coronary Stenoses. Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial. Circulation 2004;110:508-14.
32. Kaiser C, Brunner-La Rocca HP, Buser PT, et al, for the BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9.
33. Mauri L, Orav EJ, Candia SC. Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials. Circulation 2005;112:2833-9.
34. Kandzari DE, Leon MB, Popma JJ, et al. ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48:2440-7.
35. Serruys PW, Foley DP, Suttorp MJ, et al. A randomized comparison if an everolimus-eluting coronary stentwith a paclitaxel-eluting coronary stent: the SPIRIT II Trial, Eurointervention 2006;2:286-94.
36. Morice MC, Colombo A, Meier B, et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 2006; 295: 895-904
37. Chevalier B, Blanchard D, Berland J, Carrié D, Gilard M, Hanssen M. Endoprothèses actives : indications, limites et développements. Arch Mal Cœur 2005;98:1013-21.